New and future management of retinal vein occlusive disease
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

New and future management of retinal vein occlusive disease

International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology

5-6 July 2011 San Francisco, USA

Rishi P. Singh

Scientific Tracks Abstracts: JCEO

Abstract :

Retinal vein occlusions (RVOs) are the second most common form of retinal vascular disease and affects more than 100,000patients per year. The predominant causes for vision loss from RVOs include macular edema and macular ischemia. Data from historic studies recommended focal macular laser only for branch vein occlusion patients with macular edema and >20/40 vision within 3-18 months of onset and without significant retinal hemorrhages. No treatment for macular edema was recommended for central vein occlusion patients. For years, the standard of care has been extrapolated from these historic studies. However, exciting new data from five multicenter randomized controlled studies using Ranibizumab (BRAVO and CRUISE Studies),Posurdex (Ozurdex for RVO studies), and Triamcinolone Acetonide(SCORE Study) for the treatment of macular edema in vein occlusions has yielded impressive results, reshaping the management of retinal vein occlusions. The discussion will focus on the natural history of retinal vein occlusions, salient poi nts of these new trials, and an informative review of the ongoing or planned randomized clinical trials.

Biography :

Rishi Singh, MD, is a Staff Physician in the Department of Ophthalmology at Cleveland Clinic. His specialty interests include m edical and surgical retina including conditions such as diabetic retinopathy, age related macular degeneration, and retinal vein occlusions. Dr. Si ngh is also an Assistant Professor at the Lerner College of Medicine at Case Western University. He earned his medical degree from Boston University Sch ool of Medicine in Boston, Mass. He completed his residency at the Massachusetts Eye and Ear In fi rmary/Harvard University, in Boston, MA. He completed a vitreoretinal fellowship at the Cole Eye Institute of the Cleveland Clinic in Cleveland, Ohio. Dr. Singh has published over 30 articles in peer-reviewed journals and he is a member of the American Academy of Ophthalmology and the American Society of Retina Specialists. His is the principle investigator of numerous clinical trials and currently directs the Preclinical Compound Validation Program at Cole Eye Institut e which evaluates new medical and surgical treatments and provides expertise in preclinical study and human phase trial design.